Katie Murray DO, MS, FACS
Tenured Associate Professor of Urology, University of Missouri School of Medicine; Medical Director of Urological Oncology, Ellis Fischel Cancer Center, Columbia, MissouriDr. Murray is a Tenured Associate Professor of Urology at the University of Missouri School of Medicine. She serves as the Medical Director of Urological Oncology at Ellis Fischel Cancer Center in Columbia, Missouri. She serves as the Urology Medical Student Clerkship, Research Director for the Division and the Assistant Program Director for the residency program.
Dr. Murray received her undergraduate degree from Westminster College followed by Medical School at A.T. Still University to receive her Doctor of Osteopathic Medicine degree. She completed her residency in Urology at the University of Kansas followed by a Society of Urological Oncology fellowship at Memorial Sloan Kettering Cancer Center in New York City completed in 2016. While at the University of Missouri she completed a Master of Science degree in Academic Medicine.
She has published over 70 peer-reviewed journal articles as well as book chapters. She has given presentations in the area of urological oncology at various regional, national, and international meetings.
She currently serves as a Deputy Editor for the journal Urology and editorial reviewer for many of journals in urology and medical education. She serves as the site principal investigator for many clinical trials and the Chair of the Protocol Review and Monitoring Committee at Ellis Fischel Cancer Center, as well as for local investigator-initiated trials. She is on the genitourinary committee of Alliance clinical trials cooperative group and serving as the cancer center site PI for all oncology trials. She is the South Central Section elected representative to the AUA Young Urologists Committee and also serves in leadership roles for the Young Urologic Oncology clinical trials symposium of the SUO. She is board certified by the American Board of Urology.
She remains an active member of organized urology and urological oncology with clinical and research interests in urothelial cell carcinoma and impact of interventions and treatments on patients’ functional life.
Disclosures
Paid speaker and consultant for Urogen Pharma.